Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | KCNB1 | Q14721 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901645 | 0.92 | CNR1 (0.65) | CNR1KMT2AEPHX2CA1CA2 | |
| SCHEMBL4638154 | 0.89 | CNR1 (0.72) | CNR1KMT2AFPR2MEN1HTT | |
| SCHEMBL4637371 | 0.84 | CNR1 (0.69) | CNR1KMT2AEPHX2CA1CA2 | |
| SCHEMBL4901257 | 0.84 | CNR1 (0.60) | CNR1KMT2AEPHX2CA1CA2 | |
| SCHEMBL4637254 | 0.84 | CNR1 (0.72) | CNR1KMT2AEPHX2SMN1; SMN2FPR2 | |
| SCHEMBL4110390 | 0.83 | MEN1 (0.62) | KMT2AEPHX2SMN1; SMN2MEN1LMNA | |
| SCHEMBL4901135 | 0.83 | CA2 (0.64) | CNR1KMT2AEPHX2CA1CA2 | |
| SCHEMBL4637704 | 0.82 | CNR1 (0.71) | CNR1KMT2ACA1CA2CA9 | |
| SCHEMBL4899334 | 0.81 | HTT (0.62) | CNR1KMT2AEPHX2CA1CA2 | |
| SCHEMBL1492786 | 0.80 | ROCK2 (0.52) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807390-A4 | ARYLALKYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORP (US) | 2008-07-02 | — | — | EP | claimed |
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | NEUROGEN CORPORATION (US) | 2008-01-10 | — | — | US | claimed |
| EP-1807390-A2 | ARYLALKYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2007-07-18 | — | — | EP | claimed |
| WO-2006052542-A2 | ARYLALKYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-05-18 | — | — | WO | claimed |
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | NEUROGEN CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | NEUROGEN CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | NEUROGEN CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | CNR1, CNR2, GPR119 | CNR1 1/4885KMT2A 1756/4885KCNA5 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.